References
- European Medicine Agency. Identification of preventable adverse drug reactions from a regulatory perspective [cited 2016 May 11]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Presentation/2013/03/WC500139874.pdf
- Pal SN, Olsson S, Brown EG. The monitoring medicines project: a multinational pharmacovigilance and public health project. Drug Safety. 2015;38:319–328.
- Ferner RE, Aronson JK. Preventability of drug-related harms – part I: a systematic review. Drug Saf. 2010;33:985–994.
- Aronson JK, Ferner RE. Preventability of drug-related harms – part II: proposed criteria, based on frameworks that classify adverse drug reactions. Drug Saf. 2010;33:995–1002.
- Benkirane R, Soulaymani-Bencheikh R, Khattabi A, et al. Assessment of a new instrument for detecting preventable adverse drug reactions. Drug Saf. 2015;38:383–393.
- Lau PM, Stewart K, Dooley MJ. Comment: hospital admissions resulting from preventable adverse drug reactions. Ann Pharmacother. 2003;37:303–305.
- Sessa M, Rossi C, Mascolo A, et al. Suspected adverse reactions to contrast media in Campania region (Italy): results from 14 years of post-marketing surveillance. Expert Opin Drug Saf. 2015;14:1341–1351.
- Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30:239–245.
- International Conference on Harmonisation E2D: post-approval safety data management: definitions and standards for expedited reporting. Oct 2014 [cited 2016 May 11]. Available from: http://www.emea.eu.int/pdfs/human/ich/394503en.pdf
- EudraLex. Volume 9. Pharmacovigilance: medicinal products for human use and veterinary products. 2011 [cited 2016 May 11]. Available from: http://ec.europa.eu/health/files/eudralex/vol-9/pdf/vol9_10-2004_en.pdf
- Gadobenic acid – summary of product characteristic [cited 2016 May 11]. Available from: https://farmaci.agenziafarmaco.gov.it/aifa/servlet/PdfDownloadServlet?pdfFileName=footer_007050_034152_RCP.pdf&retry=0&sys=m0b1l3
- Iobitridol – summary of product characteristic [cited 2016 May 11]. Available from: https://farmaci.agenziafarmaco.gov.it/aifa/servlet/PdfDownloadServlet?pdfFileName=footer_000742_032830_RCP.pdf&retry=0&sys=m0b1l3.
- Iomeprol – summary of product characteristic [cited 2016 May 11]. Available from: https://farmaci.agenziafarmaco.gov.it/aifa/servlet/PdfDownloadServlet?pdfFileName=footer_002988_028282_RCP.pdf&retry=0&sys=m0b1l3.
- Iopamidol – summary of product characteristic [cited 2016 May 11]. Available from: https://farmaci.agenziafarmaco.gov.it/aifa/servlet/PdfDownloadServlet?pdfFileName=footer_007050_024425_RCP.pdf&retry=0&sys=m0b1l3
- Gadopentetic acid – summary of product characteristic [cited 2016 May 11]. Available from: https://farmaci.agenziafarmaco.gov.it/aifa/servlet/PdfDownloadServlet?pdfFileName=footer_000708_027074_RCP.pdf&retry=0&sys=m0b1l3.
- Iopromide – summary of product characteristic [cited 2016 May 11]. Available from: https://farmaci.agenziafarmaco.gov.it/aifa/servlet/PdfDownloadServlet?pdfFileName=footer_000708_026965_RCP.pdf&retry=0&sys=m0b1l3.
- Barium sulphate – summary of product characteristic [cited 2016 May 11]. Available from: https://farmaci.agenziafarmaco.gov.it/aifa/servlet/PdfDownloadServlet?pdfFileName=footer_002988_028558_RCP.pdf&retry=0&sys=m0b1l3.
- Iodixanol – summary of product characteristic [cited 2016 May 11]. Available from: https://farmaci.agenziafarmaco.gov.it/aifa/servlet/PdfDownloadServlet?pdfFileName=footer_000908_029354_RCP.pdf&retry=0&sys=m0b1l3.
- Iohexol – summary of product characteristic [cited 2016 May 11]. Available from: https://farmaci.agenziafarmaco.gov.it/aifa/servlet/PdfDownloadServlet?pdfFileName=footer_000908_025477_RCP.pdf&retry=0&sys=m0b1l3.
- Ioversol – summary of product characteristic [cited 2016 May 11]. Available from: https://farmaci.agenziafarmaco.gov.it/aifa/servlet/PdfDownloadServlet?pdfFileName=footer_003788_027674_RCP.pdf&retry=0&sys=m0b1l3.
- Sulfur hexafluoride – summary of product characteristic [cited 2016 May 11]. Available from: https://farmaci.agenziafarmaco.gov.it/aifa/servlet/PdfDownloadServlet?pdfFileName=footer_002326_035233_RCP.pdf&retry=0&sys=m0b1l3.
- Lasser EC, Berry CC, Talner LB, et al. Pretreatment with corticosteroids to alleviate reactions to intravenous contrast material. N Engl J Med. 1987;317:845–849.
- Safety Monitoring of Medicinal Products. Guidelines for setting up and running a pharmacovigilance centre. Uppsala: WHO; 2000. [cited 2016 May 11]. Available from: http://whoumc.org/graphics/24747.pdf.